The Symposium on Advanced Wound Care (SAWC) Fall 2025 once again brought together the global wound-care community—clinicians, researchers, innovators, and decision-makers all focused on one shared goal: improving healing outcomes for patients with chronic and post-surgical wounds. This year, Oneness Biotech participated with a renewed emphasis on scientific dialogue, real-world evidence, and clinician-driven insights.
Across the three-day event in Las Vegas, our team engaged in meaningful discussions with podiatrists, plastic surgeons, nurses, and health-system leaders seeking practical, effective, patient-friendly solutions for increasingly complex wound cases. Many shared the same challenges: delayed epithelialization, high recurrence, infection, diabetic complications, increasing pressure to produce measurable healing outcomes within constrained care pathways, and cost effectiveness.
To support this growing clinical demand, Oneness Biotech hosted three Expert Talks (Dr. Liden, Dr. Chia-Ding Shih and Dr. Kapp), featuring internationally recognized physicians presenting real-world outcomes using Bonvadis® (ON101). Each session drew strong attendance and sparked active discussion on treatment strategies, patient selection, and integration with standard wound-care protocols.
Across DFUs, VLUs, and post-surgical wounds, clinicians echoed consistent themes:
- The need for therapies that accelerate wound bed optimization
- A growing emphasis on reducing inflammation early to support predictable healing
- Interest in solutions that are easy to use (Minimal workflow disruption)
- A desire for therapies that work with debridement, NPWT, grafting, and SOC
The cases presented at SAWC Fall demonstrated Bonvadis® potential to support healing across diverse wound types, ranging from long-standing, infected diabetic foot ulcers to post-Mohs surgical sites and venous leg ulcers; many of which achieved closure within weeks despite complex comorbidities.
These conversations reaffirmed the importance of collaboration between industry and frontline clinicians. Oneness Biotech remains committed to generating rigorous clinical evidence, developing practical tools for wound-care teams, and expanding global partnerships to meet the evolving needs of modern wound management.
SAWC Fall 2025 was not only a platform for presenting scientific progress— it strengthened a shared commitment across the field: ensuring patients receive faster, safer, and more complete healing solutions than ever before.
